2025 picks +50%; 2024 picks up 324%. Access Top Stocks 2026 for just $4.95 ”
Thesis
Vanda Pharmaceuticals Inc. (VNDA) has seen a quick run-up in stock price over the New Year. This is, of course, due to the FDA’s approval of Nereus for the treatment of motion sickness and specifically vomiting. The stock jumped about 21% on the announcement, and shares can currently be picked up in the high $8 range. Now, Nereus is a very new treatment, mechanistically speaking, and I expect it to be priced with a small premium come the launch sometime in early 2026. The company also has a few other upcoming catalysts, such as Bysanti, with a PUDFA date set for February 21st of this year. I expect the stock to gain a bit of momentum leading into that decision as well. 2026 should be quite a packed year for the company, and the good news is that they have the cash to split their funding across the upcoming launches and regulatory approval readiness. At current price levels, I’m buy-rated on Vanda stock and think we should see more upside come mid to late 2026.
3Q25
Vanda’s upcoming 4Q25 is set to land sometime in February. So, looking back on 3Q25 should give a bit of insight as to what we can expect. Back in October, we saw the company executing pretty well commercially while also deliberately absorbing higher costs to support a pipeline-heavy growth strategy. Revenue was mainly driven by Fanapt, as you would expect. Fanapt brought the standout momentum, with net sales rising 31% year over year to hit the $31.2 million mark. This sales figure also represented a 35% increase in prescriptions for the drug. Overall product revenues managed to reach $56.3 million, up about 18% compared to the previous year, with some steady contributions from Hetlioz and Ponvory. The company already has quite a diversified commercial base despite the recent approval of Nereus.
The somewhat bad news back in October was that we saw these gains get offset by a sharp increase in operating expenses, particularly in R&D and SG&A, since at the time the company was investing aggressively in late-stage clinical programs and regulatory activities with the push for Nereus approval. They were also trying back then to get launch readiness for other potential near-term approvals. Bysanti, or milsaperidone, was in the works for bipolar I disorder and schizophrenia and has an upcoming PDUFA date of February 21st of this year. There is also Imsidolimab, which was developed for generalized pustular psoriasis (GPP) and had its BLA submission back in mid-December 2025. So when you look at all that the company had going on at the time, it’s easy to see why those operating expenses crept up. It was a hefty investment phase and drove a wider net loss of $22.6 million for that quarter and a year-to-date loss of roughly $79.3 million. Now, for me, that’s a strategic choice by Vanda to try and prioritise long-term value creation over any near-term profitability, since Nereus is expected to contribute to sales in the near-term.
Most importantly, they managed to exit the quarter with a pretty strong cash position of $293.8 million. The company has a packed 2026, and this cash figure should give ample runway to fund operations for another 2.5 to 3 years by my calculations. Based on the last 9-month operation spend figure of $79.3 million, they have an average cash burn of $8.8 to $9.0 million per month. However, Vanda gave us a revised 2025 financial guidance that reflects a much more conservative near-term outlook. It seems they want to preserve balance sheet strength during a heavy upcoming investment year. The company’s guidance for a tightening of expected total revenues to $210 to $230 million tells me they’re looking for more measured assumptions around product growth and timing. On the other hand, the reduction in projected year-end cash to $260 to $290 million shows us the company is quite willing to deploy capital to support late-stage development for Bysanti and Imsidolimab with the upcoming regulatory engagement. There is also the launch readiness surrounding Nereus, which is expected to burn cash. Importantly, though, even at the lower end of that cash guidance, Vanda expects to end FY25 with a pretty substantial cash position.
Approval of Nereus
As you know, Vanda has just secured FDA approval for Nereus, or tradipitant. The candidate was developed in partnership with Eli Lilly (LLY). It’s a pretty big step forward in development for the treatment of motion sickness and actually marks the first new pharmacologic option in this space for over 40 years. It also goes a long way to validating how far forward they’ve come in neuropharmacology. Nereus, by targeting the substance P/neurokinin-1 (NK-1) receptor pathway, which is a central mechanism we see in the neurobiology of vomiting, the treatment can offer a mechanistically novel approach. Now, this is a lot different from current market options or much older antihistaminic or anticholinergic therapies. In their case, they are often limited by sedation and incomplete efficacy, as I’ll explain.
The approval came just a few days ago and was supported by some pretty robust Phase 3 clinical evidence from real-world provocation studies. The studies were, of course, conducted in high motion sickness events, so we’re talking open-water boat trials. We saw Nereus consistently reduce any vomiting rates by more than 50% to 70% compared with the placebo. It’s a magnitude of effect that was seen as both clinically meaningful and statistically compelling by the FDA. Now, if we look beyond just its civilian implications for those affected by motion sickness, the approval also comes with a quite useful application in military settings. Military transport has long been an area where motion-induced vomiting is recognised as an operational liability. So I see a potential market area here besides just over-the-counter sales.
What you need to know about Nereus
As I mentioned, Nereus is a first in decades: targeted therapy for motion sickness. I say first in decades here, as the drug’s form of action is very novel. It’s actually the first FDA-approved pharmacologic treatment for motion sickness with a truly new mechanism over the last 40 years or so. Now, it works by selectively blocking that neurokinin-1 (NK-1) receptor, which is the central receptor through which substance P triggers nausea in our brainstem. We then usually vomit as a result of all the sensory conflict between visual and vestibular inputs, which isn’t a great feeling. Now, unlike older antihistamines/anticholinergics, Nereus can directly interrupt the final common emetic pathway rather than just broadly suppressing our central nervous system. Those older treatment options were developed in the mid-20th century and act through a very general, non-specific central nervous system suppression. So when that general suppression takes place, we often see sedation and cognitive impairment. It doesn’t always guarantee that the vomiting outcome will be suppressed.
What I also like about Nereus is that it’s administered orally as a single dose prior to any motion exposure. So, as expected, it’s easy to take and keep with you when travelling. The current clinical studies demonstrate effectiveness over those extended real-world travel durations, like the multi-hour boat journeys. Keep in mind, however, that Nereus is more consistent with coverage for a full travel episode. So not just short, episodic relief, and expect it to be marketed as such. Clinically, it is most impactful in preventing vomiting, which is probably the most debilitating and function-limiting symptom of motion sickness, particularly when we’re in high-provocation scenarios such as rough sea travel or flying.
A word on the TAM
Now, I, for one, have never taken an anti-vomiting pill, and that’s probably the case for most adults. So what’s the target population for the drug on launch day? Well, TAM would be mostly anchored in the high prevalence of motion sickness and the existing treatment landscape. So we’re talking roughly 25% to 30% of U.S. adults, which is about 65 to 78 million people. Now, that’s the estimate for those who experience motion sickness symptoms during travel by car, plane, or boat, with actually about one-third of individuals globally highly susceptible to the condition. In that sense, it would create a pretty broad base of potential users. But we have to keep in mind that not everyone who experiences travel sickness will be willing to purchase and take a pill, especially if they only go on short journeys or experience a sick environment once a year. So that would clearly impact the TAM.
Many of these people, however, would rely on over-the-counter remedies, but an estimated 5% to 15% suffer severe, recurrent symptoms that significantly impact quality of life. So, for me, that would be a better representation of the market for Nereus since those are the people who represent the biggest contributors to sales. The broader motion sickness treatment market is estimated at about several hundred million dollars annually. So that would be a global market size forecast of around $750 to $815 million in 2025. That figure is also projected to grow throughout the decade since travel and awareness are increasing. Some analysts have actually specifically forecasted that tradipitant’s U.S. sales for motion sickness alone could exceed $100 million per year at peak.
The competition and the pricing risk
As you would expect, the landscape is pretty competitive for Nereus. However, it’s dominated by older, low-cost motion sickness remedies like Dramamine/dimenhydrinate and Bonine/meclizine. Now, these are very inexpensive OTC antihistamines we often see sold for a few dollars per pack. There are, however, quite a few prescription options, like Transderm Scop scopolamine patches, that typically cost significantly more than just the simple pills due to a controlled-release delivery. OTC generics are obviously highly price-competitive just because of how saturated the supply is. While scopolamine patches can range into the tens of dollars per patch because of the specialised formulation and prescription status. In contrast to all this, analysts expect Nereus to command somewhat of a premium price because of how differentiated its mechanism is.
I’m expecting to see it priced well above these legacy treatments, but just how much above is what will impact sales. After all, it is a motion sickness pill, and I don’t see the public willing to pay too much of a premium compared to the over-the-counter options simply because, historically, motion sickness pills have been cheap. So we can also expect the company to market heavily on the fact that Nereus has a novel mechanism with clinical proof of superior vomiting prevention. Also expect them to stress the fact that it is an acute preventive indication rather than just general symptomatic relief, so it shouldn’t have the same side effects as other options on the market.
However, if they want to see a decent penetration rate for the treatment, they will have to keep pricing as low as they can for the initial launch. The company has told us they are looking at launching the drug in the coming months, post-FDA approval. So that would put us in early to mid‑2026. I see the biggest risk coming at launch with the pricing strategy: if it’s too high, they will fail to penetrate; if it’s too low, they won’t see a meaningful impact on sales in 2026. It will be a fine balance.
Valuation
Now, despite the quick stock run-up post-FDA approval, Vanda’s valuation still seems particularly cheap. The stock currently trades at $8.82 with a market cap of about $415 million. They’re also sitting on a cash figure of $294 million, which gives it a modest enterprise value of $133 million. A decent reflection of strong liquidity relative to debt. On a revenue basis, the stock also looks attractively valued. They hold a forward EV to sales ratio of just 0.61x compared to the healthcare sector median of 3.77x, which is a significant discount with the multiple near-term regulatory catalysts coming up. This valuation also suggests that the market is primarily pricing in existing products to continue the same growth trend, while only giving limited credit for any pipeline potential. For me, that still leaves potential upside if Nereus approvals translate into meaningful revenue growth.
Looking ahead
In early 2026, we should keep a lookout for a number of important catalysts from Vanda. First, the Nereus launch in the coming few months, and what kind of pricing we see here, will be critical. Elsewhere, Bysanti has that upcoming PDUFA date, which could serve as a potential second major regulatory milestone. This should all add up to a catalyst‑rich period that could significantly influence stock momentum on the clinical side but also stock momentum from an anticipated pickup in sales.
I hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind drug development, which I now bring into my work as an investor and analyst. For the past five years, I have been active in the investing space, with the last four years dedicated to working as a biotech equity analyst alongside my lab work. My focus is on identifying promising biotechnology companies that are innovating in unique and differentiated ways, whether through novel mechanisms of action, first-in-class therapies, or platform technologies with the potential to reshape treatment paradigms. By combining my lab-based scientific expertise with financial and market analysis, I aim to deliver research that is both technically sound and investment-driven. On Seeking Alpha, I plan to write primarily about the biotech sector, covering companies at different stages of development, from early clinical pipelines to commercial-stage biotechs. My approach emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and the potential market opportunity, all while balancing financial fundamentals and valuation. My goal in publishing here is to share some insights that help investors better understand both the opportunities and of course the many risks in biotech. This is a sector where breakthrough science can translate into outsized returns, but also where careful scrutiny is essential. I look forward to contributing thoughtful analysis and engaging with readers who share an interest in this dynamic and rapidly evolving space.
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Don’t Miss Our Top Stocks for 2026 Event
Subscribe to Premium for $4.95 for your first month and secure your spot at the Top Stocks 2026 virtual event on January 6.
Get access to our data-driven 10 stock picks for 2026 and the research behind each selection, including key market themes for the year ahead.
Previous lists have delivered strong results: the 2023 picks gained 184%, the 2024 picks rose 324%, and the 2025 picks are already up more than 50%*.
*Performance as of November 28, 2025. Past performance is no guarantee for future results. Subject to Seeking Alpha’s Events Policy as available here: https://about.seekingalpha.com/events-policy.
You can’t control the market. But you can control how you invest.
Breaking stock news is now free. Create your account to stay informed — and explore the insights behind every move.
